Expertise in
35
conditions

Dr. Bijal Shah

Hematology | Oncology
Moffitt Cancer Center, Magnolia Campus
12902 Usf Magnolia Dr, 
Tampa, FL 
Accepting New Patients
Offers Telehealth
20 Years of Experience
Expertise in
35
conditions
Moffitt Cancer Center, Magnolia Campus
12902 Usf Magnolia Dr, 
Tampa, FL 

Overview

Bijal Shah is a Hematologist and an Oncologist practicing medicine in Tampa, Florida. He has been practicing medicine for over 20 years.

Dr. Shah is highly rated in 35 conditions, according to our data. His clinical expertise encompasses Mantle Cell Lymphoma (MCL), Acute Lymphoblastic Leukemia (ALL), Non-Hodgkin Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 178 peer reviewed articles and participating in 11 clinical trials. Dr. Shah is currently accepting new patients.

Graduate Institution

University Of South Florida College Of Medicine

Specialties

Hematology
Oncology

Licenses

Internal Medicine in FL

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Florida Blue
  • EPO
  • PPO
Health Alliance Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Moffitt Cancer Center, Magnolia Campus
12902 Usf Magnolia Dr, Tampa, FL 33612

Additional Areas of Focus

Dr. Shah has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating the Safety and Efficacy of AUTO1, a CAR T Cell Treatment Targeting CD19, in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia
An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating the Safety and Efficacy of AUTO1, a CAR T Cell Treatment Targeting CD19, in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia
Enrollment Status: Active_not_recruiting
Publish Date: April 08, 2026
Intervention Type: Biological
Study Drugs: Cyclophosphamide, Fludarabine, CD19-Positive CAR-T Cells
Study Phase: Phase 1/Phase 2
A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion
A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2026
Intervention Type: Drug
Study Drug: Ruxolitinib
Study Phase: Phase 2
Optimizing Cellular and Humoral Immunity to Pneumococcus by Vaccination With Pneumococcal 13-valent Conjugate Vaccine Before and After CD19-targeted CAR T-cell Immunotherapy
Optimizing Cellular and Humoral Immunity to Pneumococcus by Vaccination With Pneumococcal 13-valent Conjugate Vaccine Before and After CD19-targeted CAR T-cell Immunotherapy
Enrollment Status: Active_not_recruiting
Publish Date: January 29, 2026
Intervention Type: Biological
Study Drugs: Pneumococcal conjugate vaccine (PCV13), CD19 targeted CAR T Cell Therapy
Study Phase: Phase 2
A Phase 2 Study to Assess the Efficacy, Safety, Pharmacokinetic and Pharmacodynamic Parameters of Umbralisib in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL)
A Phase 2 Study to Assess the Efficacy, Safety, Pharmacokinetic and Pharmacodynamic Parameters of Umbralisib in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Terminated
Publish Date: January 06, 2026
Intervention Type: Drug
Study Drug: Umbralisib
Study Phase: Phase 2
A Phase I Study of Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy
A Phase I Study of Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy
Enrollment Status: Completed
Publish Date: December 04, 2025
Intervention Type: Drug
Study Drugs: CC-486, Duvelisib
Study Phase: Phase 1
A Phase 2 Study of MLN0128 (TAK-228) in Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)
A Phase 2 Study of MLN0128 (TAK-228) in Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)
Enrollment Status: Completed
Publish Date: March 03, 2025
Intervention Type: Other, Drug
Study Drug: Sapanisertib
Study Phase: Phase 2
A Single-Arm, Open-Label Phase 2 Pilot Study of Vyxeos (CPX-351) in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia
A Single-Arm, Open-Label Phase 2 Pilot Study of Vyxeos (CPX-351) in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia
Enrollment Status: Completed
Publish Date: December 12, 2024
Intervention Type: Drug
Study Drugs: Cytarabine, Daunorubicin
Study Phase: Phase 2
A Study of the Selective HDAC6 Inhibitor, ACY-1215, for the Treatment of Patients With Relapsed or Refractory Lymphoid Malignancies
A Study of the Selective HDAC6 Inhibitor, ACY-1215, for the Treatment of Patients With Relapsed or Refractory Lymphoid Malignancies
Enrollment Status: Terminated
Publish Date: August 06, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Investigator-Initiated Phase I/II Clinical Trial of Selinexor (KPT-330) and Liposomal Doxorubicin for Relapsed and Refractory Multiple Myeloma
Investigator-Initiated Phase I/II Clinical Trial of Selinexor (KPT-330) and Liposomal Doxorubicin for Relapsed and Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: January 04, 2023
Intervention Type: Drug
Study Drugs: Selinexor, Liposomal Doxorubicin, Dexamethasone
Study Phase: Phase 1/Phase 2
A Phase 1 Study of AG-636 in the Treatment of Subjects With Advanced Lymphoma
A Phase 1 Study of AG-636 in the Treatment of Subjects With Advanced Lymphoma
Enrollment Status: Terminated
Publish Date: August 25, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 9 Less Clinical Trials

178 Total Publications

Exercise Prehabilitation for Older Adults Undergoing CAR-T: Feasibility, Acceptability, and Preliminary Outcomes.
Exercise Prehabilitation for Older Adults Undergoing CAR-T: Feasibility, Acceptability, and Preliminary Outcomes.
Journal: Transplantation and cellular therapy
Published: April 15, 2026
Similar Doctors
Expertise in
55
conditions
Dr. Lubomir Sokol
Hematology | Oncology
Expertise in
55
conditions
Dr. Lubomir Sokol
Hematology | Oncology
Referral may be required

Moffitt Cancer Center, Magnolia Campus

12902 Usf Magnolia Dr, 
Tampa, FL 
 (0.1 miles away)
813-692-4147
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Lubomir Sokol is a Hematologist and an Oncologist practicing medicine in Tampa, Florida. Dr. Sokol is highly rated in 55 conditions, according to our data. His clinical expertise encompasses T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), Non-Hodgkin Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Sokol is currently accepting new patients.

Expertise in
41
conditions
Dr. Andrew Kuykendall
Hematology | Oncology
Expertise in
41
conditions
Dr. Andrew Kuykendall
Hematology | Oncology
Referral may be required

Moffitt Cancer Center, Magnolia Campus

12902 Usf Magnolia Dr, 
Tampa, FL 
 (0.1 miles away)
813-701-3769
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Andrew Kuykendall is a Hematologist and an Oncologist practicing medicine in Tampa, Florida. Dr. Kuykendall is highly rated in 41 conditions, according to our data. His clinical expertise encompasses Myelofibrosis, Polycythemia Vera, Myelodysplastic Syndrome (MDS), Myeloproliferative Neoplasms (MPN), and Bone Marrow Aspiration. Dr. Kuykendall is currently accepting new patients.

Expertise in
43
conditions
Dr. David Sallman
Hematology | Oncology
Expertise in
43
conditions
Dr. David Sallman
Hematology | Oncology
Referral may be required

Moffitt Cancer Center, Magnolia Campus

12902 Usf Magnolia Dr, 
Tampa, FL 
 (0.1 miles away)
813-566-0117
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Sallman is a Hematologist and an Oncologist practicing medicine in Tampa, Florida. Dr. Sallman is highly rated in 43 conditions, according to our data. His clinical expertise encompasses Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Sallman is currently accepting new patients.

Frequently Asked Questions about Dr. Bijal Shah

How do I make an appointment with Dr. Bijal Shah?

You can book an appointment with Dr. Bijal Shah by calling their office at 813-820-1873. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Bijal Shah a top-rated expert for Mantle Cell Lymphoma (MCL)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Bijal Shah is classified as an Elite expert for Mantle Cell Lymphoma (MCL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Bijal Shah specialize in?

While Dr. Bijal Shah is a Hematology, they have specific expertise in Mantle Cell Lymphoma (MCL), Acute Lymphoblastic Leukemia (ALL), and Non-Hodgkin Lymphoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Bijal Shah participate in research or clinical trials?

Yes. Dr. Bijal Shah has published 178 articles and abstracts on conditions like Mantle Cell Lymphoma (MCL). You can view a list of Dr. Bijal Shah's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Bijal Shah accept my insurance?

Dr. Bijal Shah accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 813-820-1873 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Shah's expertise for a condition
ConditionClose
View All 15 Distinguished Conditions
View All 15 Advanced Conditions
View All 43 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile